PCSK9 Inhibitors Market Sales to expand at a 15.8% CAGR from 2023 to 2033, Repatha-based Inhibitors to be Most Widely Used: Future Market Insights, Inc. NEWARK, Del, Jan. 11, 2023 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global PCSK9 inhibitors market to augment at a 15.8% CAGR from 2022 to 2032. By the end of the said...